Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10039153HBVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TVIS10036610HBVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TVIS10046756HBVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TVIS30007409HIVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TVIS30079485HIVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TVIS30080445HIVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TVIS30047723HIVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TVIS30047724HIVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TVIS20004024HPVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TVIS20004695HPVENSG00000181143.17protein_codingMUC16NoNo94025Q8WXI7
TCGA Plot Options
Drug Information
GeneMUC16
DrugBank IDDB04964
Drug NameOregovomab
Target IDBE0002439
UniProt IDQ8WXI7
Regulation Type
PubMed IDs15268682; 17073521
CitationsBerek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65.@@Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83.
GroupsInvestigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL